Antenatal administration of aminopropylidene diphosphonate.

Dunlop, DJ; Soukop, M.; McEwan, Helen P.

doi:10.1136/ard.49.11.955-a

Cited by 26 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In animal studies, shortening of the diaphysis of the offspring and an increase in trabeculae has been observed. Two women who had been treated with bisphosphonates during the third trimester gave birth to healthy children [7,19]. Whether exposure in the first or second trimester may lead to side effects remains unclear at present.…”

Section: Bisphosphonatesmentioning

confidence: 98%

Osteoporosis in juvenile idiopathic arthritis- a practical approach to diagnosis and therapy

et al. 2007

View full text Add to dashboard Cite

In all subgroups of juvenile idiopathic arthritis, a decrease in bone mass has been described in a high percentage of children. Recently, new pathogenetic concepts have identified muscle mass as the strongest predictor of bone mass and bone is now recognized as part of the musculoskeletal system. In addition, the sophisticated use of bone densitometry in pediatrics, including new measurement techniques, has provided the tools for a reliable assessment. A standardized diagnostic approach to the musculoskeletal system, including prophylaxis and therapy, is, therefore, mandatory in all children with JIA who do not achieve rapid remission. In this review, diagnostic and therapeutic options are being described and possibilities to incorporate them into clinical practice are suggested.

show abstract

Section: Bisphosphonatesmentioning

confidence: 98%

Osteoporosis in juvenile idiopathic arthritis- a practical approach to diagnosis and therapy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Hypocalcaemia, apart from a direct effect of BP, could also be due to fetal parathyroid suppression by maternal hypercalcaemia. 19 Furthermore, another report of a woman with metastatic breast cancer in pregnancy treated with intravenous pamidronate at the 28 th week of gestation documented no unfavourable impact on the fetus. Fetal calcium level was elevated at birth, subsequently dropped below normal and normalized 9 days after birth.…”

Section: -Cases Of Women Treated With Bps Due To Malignanciesmentioning

confidence: 98%

The use of bisphosphonates in women prior to or during pregnancy and lactation

et al. 2011

View full text Add to dashboard Cite

ObJEctIVE: the unique pharmacokinetics of bisphosphonates (bPs) in conjunction with their use by an increasing number of women at reproductive age has raised serious concerns about their safety during pregnancy and lactation. bisphosphonates cross the placenta. Animal studies have shown adverse effects on both the fetus and the mother, mostly at doses much higher than those commonly used in humans. Protracted parturition, maternal mortality, embryolethality, severe general underdevelopment and marked skeletal retardation of the fetuses (increased amount of diaphyseal bone trabeculae, decreased diaphyseal length), small fetal weight and abnormal tooth growth have been observed. DEsIGN: We conducted a thorough research of the literature in order to identify human studies concerning this issue. rEsULts: We identified a total of 78 cases involving fetuses whose mothers had been exposed to bPs before conception or during pregnancy, along with 7 cases of bPs exposure prior to or during lactation. the vast majority of mothers and infants did not demonstrate serious adverse effects. However, there were cases of shortened gestational age, low neonatal birth weight and transient hypocalcaemia of the newborns, while the very few reported cases of spontaneous abortions and congenital anomalies probably resulted from maternal underlying diseases and concomitant medication. cONcLUsION: the administration of bisphosphonates in pregnancy should be assessed in view of their potential hazardous effects on both mother and fetus. In cases of absolute or relative indications of bPs prior to pregnancy, close observation of the mother and the infant, especially during the first two weeks of life, is imperative for the successful outcome of pregnancy.

show abstract

“…Offspring of female rats treated with subcutaneous alendronate during days 11-20 of pregnancy, the period of active development of bone from mesenchyme, showed shortening of diaphysis, increase in diaphyseal bone trabeculae with a concomitant decrease in bone marrow volume but no change in cartilage volume [80]. On the other hand, two pregnant women were given intravenous pamidronate in the third trimester for metastatic breast cancer with beneficial effect to the mother and no serious adverse effects on the fetus [25,50]. Although the theoretical risk of bisphosphonates administered to a woman of child bearing age to her future fetuses has not been substantiated, it is our practice to discuss this matter with our female patients and their families.…”

Section: Teratogenic Effectsmentioning

confidence: 97%

The role of bisphosphonates in diseases of childhood

Srivastava

Alon

2003

European Journal of Pediatrics

View full text Add to dashboard Cite

Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. In recent years, bisphosphonates have been used in children for treatment of a growing number of disorders associated primarily with generalized or localized osteoporosis, metabolic bone diseases, heterotopic calcification in soft tissues, and for resistant hypercalcemia. In the present review we discuss the pharmacological aspects of bisphosphonates and related bone pathophysiology, review the pediatric literature on the role of bisphosphonates in childhood diseases and our experience with these drugs. The theoretical concerns of possible adverse effects of these drugs on the growing skeleton have not materialized in the limited pediatric clinical experience. Bisphosphonates provide the pediatrician with an opportunity to treat mineral and bone disorders of childhood which until recently did not have satisfactory therapy, at the same time, being aware of the theoretical concerns on microdamage accumulation in bone, bone quality and teratogenic potential of these drugs.

show abstract

Antenatal administration of aminopropylidene diphosphonate.

Cited by 26 publications

References 3 publications

Osteoporosis in juvenile idiopathic arthritis- a practical approach to diagnosis and therapy

Osteoporosis in juvenile idiopathic arthritis- a practical approach to diagnosis and therapy

The use of bisphosphonates in women prior to or during pregnancy and lactation

The role of bisphosphonates in diseases of childhood

Contact Info

Product

Resources

About